Condition or disease | Intervention/treatment | Phase |
---|---|---|
High Grade Glioma BRAF V600E BRAF V600K Anaplastic Astrocytoma Anaplastic Pleomorphic Xanthoastrocytoma Gliosarcoma Glioblastoma | Drug: Encorafenib Drug: Binimetinib Biological: Research Bloods Biological: Tumor Tissue | Phase 2 |
Primary Objective Estimate the efficacy of combination treatment with encorafenib and binimetinib, as measured by response rate (RANO criteria), in patients with recurrent BRAF V600E/K-mutated malignant glioma (MG) and anaplastic pleomorphic xanthoastrocytoma (PXAs).
Secondary Objectives
There are two arms: medical and surgical. Subjects on the surgical arm must have a high-grade glioma or a known BRAF-mutated low-grade glioma with high clinical suspicion for progression to high-grade.
Medical: Following enrollment, patients will receive encorafenib and binimetinib at the FDA-approved dose of 450 mg of encorafenib once daily and the FDA-approved dose of 45 mg of binimetinib twice daily separated by 12 hours, continuously in 28-day cycles until progression or unacceptable toxicity. Patients will be followed by routine blood work, and general and neurological examination. A brain MRI will be performed prior to every odd-numbered cycle (every 8 weeks). Response will be assessed by RANO criteria. Patients may remain on study and receive treatment until progression or other reason.
Surgical: These subjects will take encorafenib and binimetinib in combination at their FDA-approved doses for 10-14 days prior to surgery. The last dose of both drugs will be administered two hours prior to surgery. Specimens will be collected during surgery. After surgery, the subjects will not take further encorafenib or binimetinib until a study visit to assess their neurological exam, physical exam, and performance status, at 2-6 weeks post-operatively. At time of restarting combination treatment, subjects will follow the schedule for the medical cohort, and will continue treatment until progression.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 62 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase II Study of Binimetinib in Combination With Encorafenib in Adults With Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor |
Actual Study Start Date : | July 29, 2019 |
Estimated Primary Completion Date : | July 2022 |
Estimated Study Completion Date : | July 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Treatment Cohort 1 AA & GBM
Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle Research Bloods |
Drug: Encorafenib
450mg QD 28 day cycle
Drug: Binimetinib 45mg BID 28 day cycle
Biological: Research Bloods Baseline; pre-cycle 3; Pre-cycle 7; off Treatment
Other Name: Circulating Tumor DNA
|
Experimental: Treatment Cohort 2 anaplastic PXAs
Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle Research Bloods |
Drug: Encorafenib
450mg QD 28 day cycle
Drug: Binimetinib 45mg BID 28 day cycle
Biological: Research Bloods Baseline; pre-cycle 3; Pre-cycle 7; off Treatment
Other Name: Circulating Tumor DNA
|
Experimental: Surgical Arm
Pre-op -14 days: Encorafenib 450mg QD and Binimetinib 45mg BID last dose of both drugs 2hrs prior to surgery Tumor; research blood; CSF samples post surgery: Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle |
Drug: Encorafenib
450mg QD 28 day cycle
Drug: Binimetinib 45mg BID 28 day cycle
Biological: Research Bloods Baseline; pre-cycle 3; Pre-cycle 7; off Treatment
Other Name: Circulating Tumor DNA
Biological: Tumor Tissue at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides
|
Experimental: Treatment Cohort 3 Other Tumors
Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle Research Bloods |
Drug: Encorafenib
450mg QD 28 day cycle
Drug: Binimetinib 45mg BID 28 day cycle
Biological: Research Bloods Baseline; pre-cycle 3; Pre-cycle 7; off Treatment
Other Name: Circulating Tumor DNA
|
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
The following intervals from previous treatments are required to be eligible:
Exclusion Criteria:
Impaired cardiovascular function or clinically significant cardiovascular disease including, but not limited to, any of the following:
3.4 Additional Inclusion Criteria for Surgical Arm
Patients must meet the above inclusion / exclusion criteria for consideration with one exception. Patients with a BRAF-V600 E or K mutated low-grade glioma for whom there is a strong clinical suspicion of progression to high-grade would also be eligible for this arm. Additionally:
Contact: Schreck, MD | 410-955-8837 | ksolt1@jhmi.edu | |
Contact: Michaella Iacoboni, RN | 410-955-4009 | msheeh13@jhmi.edu |
United States, Alabama | |
UAB Comprehensive Cancer Center | Recruiting |
Birmingham, Alabama, United States, 35294-3410 | |
Contact: Thiru Pillay, RN 205-934-1842 thiru@uab.edu | |
Principal Investigator: Burt Nabors, MD | |
United States, California | |
Jonsson Comprehensive Cancer Center at UCLA | Not yet recruiting |
Los Angeles, California, United States, 90095 | |
Contact: Timothy Cloughesy, MD 310-825-5321 TCloughesy@mednet.ucla.edu | |
Principal Investigator: Timothy Cloughesy, MD | |
United States, Maryland | |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting |
Baltimore, Maryland, United States, 21231 | |
Contact: Michaella Iacoboni, RN 410-955-4009 msheeh13@jhmi.edu | |
Contact: Tamara Dobson-Brown, BS 443-614-2818 tdobson1@jhmi.edu | |
Sub-Investigator: Matthias Holdhoff, MD | |
Sub-Investigator: Stuart Grossman, MD | |
Principal Investigator: Karisa Schreck, MD | |
United States, Michigan | |
Henry Ford Hospital | Recruiting |
Detroit, Michigan, United States, 48202 | |
Contact: Amber Lewis ALEWIS7@hfhs.org | |
Principal Investigator: Tobias Walbert, MD | |
United States, North Carolina | |
Wake Forest University Comprehensive Cancer Center | Recruiting |
Winston-Salem, North Carolina, United States, 27157 | |
Contact: Clinical Trials Office 336-713-6771 | |
Contact: Roy Strowd 336-716-2357 | |
Principal Investigator: Roy Strowd, MD | |
United States, Pennsylvania | |
Abrams Cancer Center of the University of Pennsylvania | Recruiting |
Philadelphia, Pennsylvania, United States, 19104 | |
Contact: Clinical Trials Office-Abrams Cancer Center 800-474-9892 | |
Principal Investigator: Arati Desai, MD |
Study Director: | Stuart A Grossman, MD | ABTC |
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | May 31, 2019 | ||||||||
First Posted Date ICMJE | June 4, 2019 | ||||||||
Last Update Posted Date | May 24, 2021 | ||||||||
Actual Study Start Date ICMJE | July 29, 2019 | ||||||||
Estimated Primary Completion Date | July 2022 (Final data collection date for primary outcome measure) | ||||||||
Current Primary Outcome Measures ICMJE |
Tumor radiographic response per RANO for 3 treatment cohorts [ Time Frame: 1 year ] Number of participants from each treatment cohort with response as defined by Response Assessment in Neuro-oncology (RANO) criteria: Complete Response (CR)= no change in size of T1-gadolinium-enhancing (T1-Gd+) disease, stable or reduced T2/FLAIR signal, no new lesion, no corticosteroid use, and stable or improved clinical status; Partial Response (PR)= ≥50% change in size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status; Stable Disease (SD)= <50% reduction to <25% increase size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status; Progressive Disease (PD)= ≥25% increase size of T1-Gd+ disease, or increased T2/FLAIR signal, or presence of new lesion, or worsening clinical status.
|
||||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||||
Change History | |||||||||
Current Secondary Outcome Measures ICMJE |
|
||||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||
Descriptive Information | |||||||||
Brief Title ICMJE | Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG | ||||||||
Official Title ICMJE | A Phase II Study of Binimetinib in Combination With Encorafenib in Adults With Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor | ||||||||
Brief Summary | The goal of this study is to estimate the efficacy of encorafenib and binimetinib as measured by radiographic response in recurrent high-grade primary brain tumors. | ||||||||
Detailed Description |
Primary Objective Estimate the efficacy of combination treatment with encorafenib and binimetinib, as measured by response rate (RANO criteria), in patients with recurrent BRAF V600E/K-mutated malignant glioma (MG) and anaplastic pleomorphic xanthoastrocytoma (PXAs). Secondary Objectives
There are two arms: medical and surgical. Subjects on the surgical arm must have a high-grade glioma or a known BRAF-mutated low-grade glioma with high clinical suspicion for progression to high-grade. Medical: Following enrollment, patients will receive encorafenib and binimetinib at the FDA-approved dose of 450 mg of encorafenib once daily and the FDA-approved dose of 45 mg of binimetinib twice daily separated by 12 hours, continuously in 28-day cycles until progression or unacceptable toxicity. Patients will be followed by routine blood work, and general and neurological examination. A brain MRI will be performed prior to every odd-numbered cycle (every 8 weeks). Response will be assessed by RANO criteria. Patients may remain on study and receive treatment until progression or other reason. Surgical: These subjects will take encorafenib and binimetinib in combination at their FDA-approved doses for 10-14 days prior to surgery. The last dose of both drugs will be administered two hours prior to surgery. Specimens will be collected during surgery. After surgery, the subjects will not take further encorafenib or binimetinib until a study visit to assess their neurological exam, physical exam, and performance status, at 2-6 weeks post-operatively. At time of restarting combination treatment, subjects will follow the schedule for the medical cohort, and will continue treatment until progression. |
||||||||
Study Type ICMJE | Interventional | ||||||||
Study Phase ICMJE | Phase 2 | ||||||||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||||||
Condition ICMJE |
|
||||||||
Intervention ICMJE |
|
||||||||
Study Arms ICMJE |
|
||||||||
Publications * | Not Provided | ||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status ICMJE | Recruiting | ||||||||
Estimated Enrollment ICMJE |
62 | ||||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||||
Estimated Study Completion Date ICMJE | July 2023 | ||||||||
Estimated Primary Completion Date | July 2022 (Final data collection date for primary outcome measure) | ||||||||
Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
3.4 Additional Inclusion Criteria for Surgical Arm Patients must meet the above inclusion / exclusion criteria for consideration with one exception. Patients with a BRAF-V600 E or K mutated low-grade glioma for whom there is a strong clinical suspicion of progression to high-grade would also be eligible for this arm. Additionally:
|
||||||||
Sex/Gender ICMJE |
|
||||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||||
Accepts Healthy Volunteers ICMJE | No | ||||||||
Contacts ICMJE |
|
||||||||
Listed Location Countries ICMJE | United States | ||||||||
Removed Location Countries | |||||||||
Administrative Information | |||||||||
NCT Number ICMJE | NCT03973918 | ||||||||
Other Study ID Numbers ICMJE | ABTC 1802 UM1CA137443 ( U.S. NIH Grant/Contract ) |
||||||||
Has Data Monitoring Committee | Yes | ||||||||
U.S. FDA-regulated Product |
|
||||||||
IPD Sharing Statement ICMJE |
|
||||||||
Responsible Party | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | ||||||||
Study Sponsor ICMJE | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | ||||||||
Collaborators ICMJE |
|
||||||||
Investigators ICMJE |
|
||||||||
PRS Account | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | ||||||||
Verification Date | May 2021 | ||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |